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Abstract
Objective This study aims to investigate the immunoprotection
of recombinantEg.P29 (rEg.P29) vaccine and analyze the under-
lying mechanism in sheep.
Methods Three groups of male sheep were immunized sub-
cutaneously with rEg.P29 and PBS, Freund’s complete adju-
vant as controls, respectively. After prime-boost vaccination,
the sheep were challenged with encapsulated Echinococcus
granulosus eggs. The percentage of protection in sheep was
determined 36 weeks after the infection. Humoral immune
response was analyzed for specific IgG, IgG1, IgG2, IgM
and IgE levels. Moreover, cytokines including interferon
(IFN)-γ, interleukin (IL)-2, IL-4,and IL-10 were also
evaluated.
Results Immunization with rEg.P29 induced protective immune
responses up to 94.5 %, compared with immunoadjuvant group.
The levels of specific IgG, IgG1, IgG2, and IgE aswell as IFN-γ,
IL-2, and IL-4 significantly increased after two immunizations
(P < 0.05); however, the levels of IgM and IL-10 did not show
difference.
Conclusion rEg.P29 showed Immunoprotection and induced
Th1 and Th2 immune responses; hence, rEg.P29 is a potential
vaccine for E. granulosus infection.
Keywords rEg.P29 . Echinococcus granulosus .
Immunoprotection . Vaccine
Introduction
Echinococcus granulosus (E. granulosus) is a cestode parasite
that causes endemic zoonosis between human and animals,
leading to public health problem and economic loss in the
developing and developed countries (Mandal and Mandal
2012; Brunetti and Junghanss 2009). Sheep is a crucial inter-
mediate host in the parasite cycle of E. granulosus (Atkinson
et al. 2013). Carcasses and offal of sheep after home slaughter
are always discarded in poor and remote communities and
then dogs scavenge these, completing the parasite cycle and
putting communities at risk of cystic echinococcosis (Li et al.
2014). Therefore, as mentioned above, it is very important to
control the infection in sheep.
Vaccination is the most effective strategy for the prevention
of infectious diseases worldwide. In E. granulosus infection,
some vaccine candidates have proven to be highly protective
in mice (Li et al. 2012; Sun et al. 2011; Shi et al. 2009), goats,
sheep and bovines (Read et al. 2009; Chow et al. 2008; Dutton
et al. 2012; Gauci et al. 2005; Heath et al. 2012a; Lightowlers
et al. 1999; Woollard et al. 2000). Representative vaccine
EG95 induced immunoprotection up to 95 % to 96 %.
However, due to complicated multi-cellular pathogen and host
interplay, there is still no vaccine approved for clinical use. In
this study, we will sought to evaluate the potential of Eg.P29
as a vaccine candidate for sheep.
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Eg.P29 was first described by Gonzalez et al. as a novel
29 kDa antigen in hydatid cyst fluid (Gonzalez et al. 2000).
Our previous study confirmed that rEg.P29 could protect
against E. granulosus secondary infection in mice (Shi et al.
2009). However, mice are not the intermediate hosts for
E. granulosus infection in human. Furthermore, secondary
infection in mice is very different from natural infection and
the result is not convincing for the mimicking challenge. In the
present study, we will evaluate the immunoprotection of re-
combinant Eg.P29 (rEg.P29) against an oral challenge infec-
tion with E. granulosus eggs in sheep.
Materials and methods
Animals and parasites
Thirty male sheep, 4–6 months old, were obtained from
Lanzhou Veterinary Research Institute, Chinese Academy of
Agricultural Sciences. The sheep were first scanned negative
by serological test and then randomly allocated into three groups
(eight sheep/group): rEg.P29, Freund’s complete adjuvant
(FCA), and PBS groups. An additional 2 sheep/group were pre-
pared for accidental death. The sheep were all raised on the same
farm. All experiments were approved by the Ethics Committee
of Ningxia Medical University. E. granulosus eggs were also
obtained from the institute. Before the oral challenge, 3000 fresh-
ly collectedE. granulosus eggs were packaged into each capsule.
Preparation of rEg.P29
The Eg.P29 gene was obtained from hydatid cysts of patients in
General Hospital of Ningxia Medical University (The Chinese
strain of the gene was recorded into GenBank: sequence number
AF078931. Plasmid Eg.P29/pET28a was constructed and
expressed in Escherichia coli by our lab previously (Shi et al.
2009)). Briefly, the plasmid Eg.P29/pET28a was transformed
into E.coli BL21 (DE3) pLysS, and protein expression was in-
duced at 37 °C for 8 h in the presence of 0.4 mM isopropyl-b-D-
thiogalactoside (IPTG, Invitrogen). Subsequently, rEg.P29 with
6 × histidines (His) tag in the C terminus was purified by nickel
chelate affinity chromatography (Novagen) according to the
manufacturer’s instructions. The purified rEg.P29 was identified
with 12 % sodium dodecyl sulfate–polyacrylamide gel
electrophoresis(SDS-PAGE) and the Western blot method.
Briefly, rEg.P29 was resolved using 12 % SDS–PAGE and elec-
trophoretically transferred onto a nitrocellulose membrane. After
blocking with 5 % skim milk at room temperature (RT) for 2 h,
the membrane was probed with anti-His-tag mouse monoclonal
antibody (MAb) (1:200) or pooled sera (1:200) from sheep in-
fected with E. granulosus eggs, at RT for 1 h. After washing, the
blot was incubated with horseradish peroxidase (HRP)-conjugat-
ed goat anti-mouse IgG or rabbit anti-sheep IgG at RT for 1 h
before detection with West Pico Chemiluminescent Substrate
(Thermo Scientific, Rockford, IL). The protein concentration
was determined using Bradford method (Bradford 1976).
Vaccination and challenge with E. granulosus eggs
Sheep in three groups were subcutaneously vaccinated in the
neck region with the corresponding treatments on day 1: PBS
group, 100 μl of PBS; FCA group, 50 μl of FCA and 50 μl of
PBS; and rEg.P29 group, 50 μg of rEg.P29 (1 μg/μl) emulsi-
fied with 50 μl of FCA. The second immunization was ad-
ministered with the same preparation on day 28, except that
FCA was replaced by Freund’s incomplete adjuvant. Four
weeks after the last vaccination, each sheep was orally chal-
lenged with encapsuled freshly 3000 E. granulosus eggs. The
percentage of protection in sheep was determined according to
the Dempster method (Dempster and Harrison 1995).
Immunoprotection is calculated as: protection (%) = (1 − aver-
age of cysts in the test group/average of cysts in the control
group) × 100.
Detection of specific antibodies
Serum antibody responses were detected by ELISA at 0, 1, 2,
4, 6, 9, 12, 20, 36, and 44 weeks after immunization. 96-well
microplates (Sino-American Biotechnology Company,
Beijing, China) were coated with 100 μl of rEg.P29 (0.1 μg/
μl) per well and incubated overnight in 0.1M carbonate buffer
(pH 9.6) at 4 °C. Serum samples were diluted (1:100) in PBS
with 0.05 % Tween-20 (PBST) and incubated at 37 °C for 1 h
in duplicate. Bound antibody was detected by HRP-
conjugated goat anti-sheep IgG, IgG subclass, IgE, and IgM
(Novagen) at1:1000 dilution in PBST. Optical density (OD)
values were read at 490 nm (Bio-Rad).
The sheep were scanned negatively using ELISA coated
with hydatid cysts crude antigens. Briefly, 96-well microplates
were coated with 100 μl of crude soluble antigens(0.1 μg/μl)
from hydatid cysts per well, other steps are as well as above
mentioned.
Determination of cytokines
The OD value of serum cytokine was detected through ELISA
in accordance with the manufacturer’s instructions (Jinmei
Biotech Company, Beijing, China). Serum samples were di-
luted (1:100) in PBS and tested in duplicate. Diluted serum
was added into the 96-well microplates and incubated for 2 h
at 37 °C. After washing with PBST, 50 ng of biotin-
conjugated antibody was added to each well and then incubat-
ed again for 2 h at 37 °C. After washing, peroxidase-labeled
streptavidin was added to the wells and incubated for 1.5 h at
37 °C. The wells were then washed and incubated with the
substrate for 0.5 h at 37 °C. Finally, the reaction was
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terminated by adding 50μl of 2M sulfuric acid. TheOD value
was determined at 490 nm using an ELISA reader (Bio-Rad).
A standard curve was prepared to calculate cytokine
concentration.
Statistical analysis
All statistical analyses were performed using Prism 5.0
(GraphPad Software Inc., CA, USA). Data were obtained
from at least three independent experiments and represented
as mean ± standard error. Statistical analysis was conducted
using the non-parametric (Mann-Whitney) t-test or Student’s
t-test. Results were considered significant at P < 0.05.
Results
Expression and purification of rEg.P29
rEg.P29 was successfully expressed and purified. The purity and
size of the recombinant protein was identified through SDS–
PAGE and the Western blot. The recombinant protein showed
a high purity and a molecular weight of 31 kDa as predicted
(Fig. 1).
rEg.P29 immunization reduced the number of developing
cysts
The sheep were euthanized at the end of 44 weeks, and cysts
were counted to determine the protective effects (Fig. 2).
Significant reduction of cyst load was found in the rEg.P29
group compared with the control group which immunized
with PBS or FCA at 9 months post-infection (Table 1). The
immunoprotection is 94.5 % and 95.1 % (compared with PBS
and FCA group).
rEg.P29 immunization effectively induced humoral
responses
The immunization with rEg.P29 induced significantly higher
levels of specific IgG, IgG1, and IgG2 (Figs. 3a, b, c and d)
one week after the first immunization compared with those
before the immunization (P < 0.01). At 2 and 4 weeks after
the first immunization, the levels of IgG, IgG1, and IgG2
reduced slowly but remained statistically different from those
in PBS or FCA group (P < 0.01). Two weeks after the last
Fig. 1 Expression and identification of rEg.P29. Figure 1a shows the
results of the SDS-PAGE analysis. The gel was stained by Coomassie
brilliant blue: M, molecular weight markers; line 1, E. coli lysates without
IPTG induction; line2, E. coli lysates with IPTG induction; and line 3,
purified rEg.P29. Figure 1b shows the results of the Western blot analysis
of rEg.P29. Line1, PBS as negative control; line 2, the purified rEg.P29
protein was probed with anti-His-tag mouse MAbs; line 3, the purified
rEg.P29 protein was probed with pooled sera from infected sheep
Fig. 2 Hydatid cysts in sheep liver. Sheepwere euthanized, and the livers
were immediately isolated in the laboratory. Cysts on the liver surface
were examined carefully; the liver was then sliced into 3 mm pieces to
check and record the number of cysts. Fibrotic and calcified cysts were
regarded as invalid cysts. Immunoprotection was calculated through cyst
reduction method in accordance with the following formula: protection
(%) = (1 − average of cysts in the test group/average of cysts in the control
group) × 100. Cysts can grow on the surface and inside on the liver.
Figure 2a shows cysts inside of the liver. Figure 2b shows cysts on the
surface of the liver
Table 1 The number of hydatid cysts and immunoprotection of the
rEg.P29 vaccine in sheep
Group No. of cysts in individual sheep Mean ± SEM
PBS 44 34 26 13 22 36 27 20 27.75 ± 3.49
FCA + PBS 41 21 34 19 13 17 30 25 25.00 ± 3.33
rEg.P29 3 1 1 0 2 1 1 2 1.375 ± 0.324*#
The number of hydatid cysts in rEg.P29 group shows significant reduced
from group PBS (*P < 0.0001) or group FCA + PBS (#P < 0.0001) by
Student’s t-test.
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immunization, the levels of specific IgG, IgG1, and IgG2 in
the rEg.P29 group were higher than those in PBS or FCA
group (P < 0.01). Specific IgE level was not significantly
different until the second week after prime immunization.
Interestingly, IgE level slowly increased in the rEg.P29 group
and was significantly different (P < 0.01) from that in the two
control groups respectively. After the second immunization,
the levels of specific IgG, IgG1, IgG2, and IgE in the rEg.P29
group significantly increased and peaked at 9 weeks (1 week
after the infection).
rEg.P29 immunization induced Th1/Th2 cytokine
responses
IFN-γ, IL-4, and IL-10 levels in serum as indicators of Th1 and
Th2 immune polarization were measured; IL-2 was used as a
marker of T lymphocyte proliferation (Dematteis et al. 1999).
IL-2 and IFN-γ levels in the rEg.P29 group increased statisti-
cally compared with that in PBS or FCA groups (P < 0.01) at
week 6 (2 weeks after the boost immunization) and then se-
quentially increased at week 9 (1 week after the infection)
(Fig. 4a and b). Serum IL-4 levels in vaccinated sheep were
higher than those in the PBS group after the immunization
(P < 0.01) and peaked after the infection(P < 0.01). IL-10 level
did not significantly increase in the immunized group compared
with that in the control group (Fig. 4d) (P > 0.05).
Discussion
The present study explored the protective effects of
immunizating sheep with rEg.P29 against the challenge with
E. granulosus eggs, and the associated immune response. It’s
not the first time to confirm a vaccine in sheep. Before the
study, vaccination of sheep and other livestock with EG95
has been proven to generate up to 95 % protective efficacy
(Lightowlers et al. 1999; Heath et al. 2012b). Furthermore,
the immunological mechanism of vaccine EG95 has been
investigated widely. In our study, evidently, immunization
with rEg.P29 leads to effective immunoprotection com-
pared with the other two control groups. That will provide
an experimental foundation for rEg.P29 to be a potential
vaccine.
Specific IgG, IgG1, IgG2, and IgE levels significantly in-
creased in sheep immunized with rEg.P29. This finding indi-
cated that prime-boost immunization with rEg.P29 induced po-
tent IgG-predominant immune responses against E. granulosus
infection. This result is consistent with EG95 vaccination ef-
fects in sheep (Heath et al. 2003; Heath and Koolaard 2012).
Protection of EG95-vaccination sheep against challenge infec-
tion with E. granulosus were IgG-derived and complement-
dependent (Gauci et al. 2005). But in the present study, whether
generated IgG activates complement system for lysis of the
parasite, need further studies. Furthermore, studies have
Fig. 3 OD value profiles of IgG and IgE in immunized sheep before and
after infection. Ten time points were selected for serum antibody
examination: week 0 (before immunization), week 1 (first
immunization), week 2 (1 week after the first immunization), week 4
(second immunization), week 6 (2 weeks after the second
immunization), week 9 (1 week after the infection), week 12 (4 weeks
after the infection), week 20 (12 weeks after the infection), week 36
(28 weeks after the infection), and week 44 (36 weeks after the
infection). *P < 0.05 and **P < 0.01 indicate significant difference
between PBS and rEg.P29 groups. #P < 0.05 and ##P < 0.01 denote
significant difference between FCA and rEg.P29 groups
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reported that determination of anti-P29 IgG levels of patients
with CE in post-surgical follow-up could be a valuable prog-
nostic tool for clinical management of human CE cases
(Boubaker et al. 2014). Elevated IgE in this studymay stimulate
mast cells and basophils for elimination of the parasite as pre-
viously reported (Pirestani et al. 2014). No significant differ-
ence of serum IgM (data not shown) indicates that rEg.P29
cannot induce this antibody generation.
Cytokine response indicates Th1/Th2 polarization, which
plays a crucial role in cystic localization and clinical stage
(Zhang et al. 2008; Zhang et al. 2012). General speaking,
Th1 cytokines induce protective cellular immune response,
and Th2 cytokines promote the stimulation of humoral im-
mune response that are responsible for parasite evasion from
immune surveillance (Brunetti and Junghanss 2009;
McManus et al. 2012). In our study, both IFN-γ and IL-4
levels evidently increased after the vaccination, indicating that
both Th1 and Th2 immune response have been activated by
rEg.P29. Significant increase of IFN-γ at 9th week (one week
after infection) can be as an indicator of greater Th1 than Th2
response. Significant elevated level of IL-4 at 6th week (two
weeks after vaccination) suggests that IL-4 is mainly induced
by rEg.P29. IL-4 level at 9th week (one week after infection)
in vaccination group showed no significant difference with
other two control groups, one possible explanation is either
early infection induced Th1-polarized immune response that
inhibit the Th2 levels or infection induced strong Th2 immune
response in the control group, which covers up the slow
increase of IL-4 levels in the vaccinated group. Studies
manifested that Th1 dominated at the early stage of the
infection and subsequently Th2 is predominant in the
late of the infection (Zhang et al. 2008). In our studies,
no significant difference of IL-10 between the before-
and after- immunization was found, compared with the
two control groups. Earlier researches on effects of IL-
10 in E. granulosus infection or other recombinant vac-
cine candidates’ tests support our result (Rigano et al.
2007; Fraize et al. 2005; Ortona et al. 2003). We found
high level of IL-10 at the end of chronic infection, and
this may be involved with evasion of E. granulosus to
host immune response as previous reported (Amri et al.
2009).
In the present study, there was no significant difference
between FCA group and PBS group in cyst reduction, anti-
body and cytokine response, demonstrating that this
immunoadjuvant could not induce immune response
against the parasite infection directly. How the adjuvant
is participating in immunoprotection of rEg.P29 is un-
clear. Because this adjuvant is not commonly used in
sheep immunization, we will optimize our immunization
strategy in the further studies by selecting effective Quil
A as adjuvant according to mature method in EG95
associated references (Heath et al. 2003; Heath and
Koolaard 2012; Lightowlers and Heath 2004).
In summary, immunization with rEg.P29 induced protec-
tive immunity against challenge of sheep with natural infec-
tion of E.granulosus eggs. This immunoprotection is due to
humoral and cellular immune responses. The vaccine may
prevent sheep transmission of the parasite and impede the
natural parasite life cycle.
Fig. 4 Detection of cytokines in
immunized sheep before and after
the infection. Different stages
were selected for cytokine
examination: week 0 (before
immunization), week 6 (2 weeks
after the second immunization),
week 9 (1 week after infection),
and week 44 (36 weeks after
infection). *P < 0.05 and
**P < 0.01 indicate significant
differences between PBS and
rEg.P29 groups. #P < 0.05 and
##P < 0.01 denote significant
differences between FAC and
rEg.P29 groups. The assay for
cytokine analysis was repeated
five times.
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